research Involvement of neurosteroids in the anxiolytic-like effects of AC-5216 in mice
AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
Search
for
Sort by
Research
570-600 / 1000+ resultsresearch Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata
The document did not conclude on apremilast's effectiveness for severe alopecia areata.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research 1409 Temporary cell cycle arrest by ALRN-6924: A novel, p53-targeting strategy to protect human scalp hair follicles against cyclophosphamide-induced alopecia
ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
research Clinical perspective on management of key adverse events with sacituzumab govitecan
Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
research Sisaipho alopecia areata treated with tofacitinib and oral minoxidil
Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
research Dutasteride for Androgenetic Alopecia—Words of Caution
Dutasteride's effect on hair loss treatment is uncertain and should be used cautiously.
research Etoricoxib
A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
research Alopecia areata in a patient with psoriatic arthritis and C rohn's disease receiving etanercept
Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.
research Thrombotic risk minimization for D iane‐35 and generics
The use of Diane-35 and its generics significantly decreased in the Netherlands.
research 453 Signaling by Senescent Melanocytes Induces New Hair Growth and Informs Hair Growth-Activating Injectable for Androgenetic Alopecia
AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.
research Successful treatment of alopecia universalis with abrocitinib: a case report
Abrocitinib may effectively treat stubborn alopecia universalis.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
Social media can help compare the effectiveness and safety of new arthritis medications.
research The Burden of Alopecia Areata and Management with Baricitinib in the United Arab Emirates: A Narrative Review
Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
research Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
research Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Weekly azathioprine pulse versus betamethasone oral mini-pulse in the treatment of moderate-to-severe alopecia areata
Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
research FASCE, the benefit of spironolactone for treating acne in adult females: study protocol for a randomized double-blind trial
Spironolactone is a promising alternative to antibiotics for treating acne in adult females.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Tofacitinib: A Promising Treatment for Adolescent Alopecia Areata
Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
research Tofacitinib for the treatment of alopecia areata in preadolescent children
Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.